AstraZeneca Finds Two More Potential Partners For Imfinzi
Combo Data At ESMO Supports Use With CD73 And NGK2A Inhibitors
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
You may also be interested in...
Portage Buys Tarus, Gaining Cancer Assets Targeting Immune Evasion
Acquisition valued at roughly $21m upfront for two clinical and two preclinical adenosine receptor antagonists.
Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.